Short answer
Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exclusive Estyme injectable gel rights added in Canada, Australia and New Zealand.
Evolus, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive Estyme injectable gel rights added in Canada, Australia and New Zealand
- €920,000 upfront payment plus up to €1.38 million tied to regulatory approvals
- Symatese bears development and regulatory costs for the newly added territories
- 15-year initial terms from first regulatory approval, with automatic five-year renewals
Item 7.01 · Regulation FD Disclosure
- Evolus announced execution of an Amendment on August 4, 2026
- Press release furnished as Exhibit 99.1 contains the substantive Amendment details
- Regulation FD disclosure signals potentially material agreement changes for investors to review
Item EX-99.1 · Exhibit EX-99.1
- Exclusive Estyme rights expanded to Canada, Australia, and New Zealand, completing Evolus’ injectable portfolio coverage across existing commercial markets
- Addressable neurotoxin and dermal filler market approximately $500 million annually, with 60% neurotoxins and 40% dermal fillers
- Commercialization targeted for 2028, contingent on regulatory approvals and review processes
- Upfront and regulatory milestone payments, product purchases at transfer pricing, and mid-single-digit net-sales royalty owed to Symatese
- Expected international gross-margin accretion through existing commercial, digital, and distribution infrastructure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolus, Inc. 8-K filings
Get the next EOLS 8-K as it lands
Follow EOLS for push alerts, or ask the research agent what this filing means.